Korean J Hematol.  2004 Mar;39(1):16-22.

Single Center Experience of Allogeneic Peripheral Blood Stem Cell Transplantation for Acute Myeloid Leukemia

• Sung WJ
• Moon JH
• Jeon SB
• Kim DH
• Kim JG
• Sohn SK
• Suh JS
• Lee KS
• Lee KB

Abstract

BACKGROUND
Recently, peripheral blood (PB) stem cells have been used widely for allogeneic stem cell transplantation (SCT), instead of bone marrow (BM). The current study analyzed the outcome of allogeneic PBSCT for the patients with acute myeloid leukemia (AML).
METHODS
Twenty-nine patients with AML excluding AML M3 were included for the analysis. PB stem cells were collected from HLA-matched sibling donors mobilized with G-CSF with or without GM-CSF.
RESULTS
Engraftment for neutrophil and platelet were achieved in a median 15.0 days and 14.0 days, respectively. The incidence of grade II~III acute graft versus host disease (GVHD) was 82.8% (24/29 patients), while of chronic GVHD 78.6% (22/28 patients, limited 11, extensive 11). During the median follow-up of 340 days (range, 86~1,603 days), 3 years overall survival and disease free survival was 51.4% and 40.0%, respectively.
CONCLUSION
PB may be considered as a feasible source of allogeneic SCT for patients with AML.

Keyword

Allogeneic peripheral blood stem cell transplantation; Acute myeloid leukemia; Graft-versus-host disease; Graft-versus-leukemic effect

MeSH Terms

Blood Platelets
Bone Marrow
Disease-Free Survival
Follow-Up Studies
Graft vs Host Disease
Granulocyte Colony-Stimulating Factor
Granulocyte-Macrophage Colony-Stimulating Factor
Humans
Incidence
Leukemia, Myeloid, Acute*
Leukemia, Promyelocytic, Acute
Neutrophils
Peripheral Blood Stem Cell Transplantation*
Siblings
Stem Cell Transplantation
Stem Cells
Tissue Donors
Granulocyte Colony-Stimulating Factor
Granulocyte-Macrophage Colony-Stimulating Factor